pembrolizumab,nivolumab,Ipilimumab,atezolizumab,avelumab,durvalumab,cemiplimab,dostarlimab,pomalidomide
merck,bms,roche,pfizer,astrazeneca,sanofi,regeneron,gsk
['pembro']
and the winner is pembrolizumab #esmo2022 
Oncology care , to give or not to give chemo , data analysis , oncology pharamocovigilance , enthusiastic critic, twitts are not twists